This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meagher, A. K.
Right arrow Articles by Ambrose, P. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meagher, A. K.
Right arrow Articles by Ambrose, P. G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2007, p. 1939-1945, Vol. 51, No. 6
0066-4804/07/$08.00+0     doi:10.1128/AAC.01084-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Skin and Skin-Structure Infections{triangledown}

A. K. Meagher,1 J. A. Passarell,1* B. B. Cirincione,1 S. A. Van Wart,1 K. Liolios,1 T. Babinchak,2 E. J. Ellis-Grosse,2 and P. G. Ambrose3,4

Cognigen Corporation, Buffalo, New York,1 Wyeth Research, Collegeville, Pennsylvania,2 ICPD/Ordway Institute, Albany, New York,3 School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York4

Received 28 August 2006/ Returned for modification 1 December 2006/ Accepted 7 March 2007

Exposure-response analyses were performed for the microbiological and clinical efficacy of tigecycline in the treatment of complicated skin and skin-structure infections, where Staphylococcus aureus and streptococci are the predominant pathogens. A prospective method was developed to create homogeneous patient populations for PK-PD analyses. Evaluable patients from three clinical trials were pooled for analysis. Patients received a tigecycline 100-mg loading dose/50 mg every 12 h or a 50-mg loading dose/25 mg every 12 h. At the test-of-cure visit, microbiologic and clinical responses were evaluated. Patients were prospectively evaluated and classified into cohorts based on baseline pathogens: S. aureus only (cohort 1), monomicrobial S. aureus or streptococci (cohort 2), two gram-positive pathogens (cohort 3), polymicrobial (cohort 4), or other monomicrobial infections (cohort 5). A prospective procedure for combining cohorts was used to increase the sample size. Logistic regression evaluated steady-state 24-h area under the concentration-time curve (AUC24)/MIC ratio as a predictor of response, and classification and regression tree (CART) analyses were utilized to determine AUC/MIC breakpoints. Analysis began with pooled cohorts 2 and 3, the focus of these analyses, and included 35 patients with 40 S. aureus and/or streptococcal pathogens. CART analyses identified a significant AUC/MIC breakpoint of 17.9 (P = 0.0001 for microbiological response and P = 0.0376 for clinical response). The continuous AUC/MIC ratio was predictive of microbiological response based on sample size (P = 0.0563). Analysis of all pathogens combined decreased the ability to detect exposure-response relationships. The prospective approach of creating homogeneous populations based on S. aureus and streptococci pathogens was critical for identifying exposure-response relationships.

* Corresponding author. Mailing address: Cognigen Corp., 395 Youngs Rd., Buffalo, NY 14221. Phone: (716) 633-3463. Fax: (716) 633-7404. E-mail: julie.passarell{at}cognigencorp.com

{triangledown} Published ahead of print on 12 March 2007.

Antimicrobial Agents and Chemotherapy, June 2007, p. 1939-1945, Vol. 51, No. 6
0066-4804/07/$08.00+0     doi:10.1128/AAC.01084-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Nicasio, A. M., Crandon, J. L., Nicolau, D. P. (2009). In Vivo Pharmacodynamic Profile of Tigecycline against Phenotypically Diverse Escherichia coli and Klebsiella pneumoniae Isolates. Antimicrob. Agents Chemother. 53: 2756-2761 [Abstract] [Full Text]  
  • Koomanachai, P., Kim, A., Nicolau, D. P. (2009). Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. J Antimicrob Chemother 63: 982-987 [Abstract] [Full Text]  
  • Crandon, J. L., Banevicius, M. A., Nicolau, D. P. (2009). Pharmacodynamics of Tigecycline against Phenotypically Diverse Staphylococcus aureus Isolates in a Murine Thigh Model. Antimicrob. Agents Chemother. 53: 1165-1169 [Abstract] [Full Text]  
  • Bowker, K. E., Noel, A. R., MacGowan, A. P. (2008). Pharmacodynamics of Minocycline against Staphylococcus aureus in an In Vitro Pharmacokinetic Model. Antimicrob. Agents Chemother. 52: 4370-4373 [Abstract] [Full Text]  
  • Kelesidis, T., Karageorgopoulos, D. E., Kelesidis, I., Falagas, M. E. (2008). Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 62: 895-904 [Abstract] [Full Text]  
  • MacGowan, A. P., on behalf of the BSAC Working Parties on Resistanc, (2008). Clinical implications of antimicrobial resistance for therapy. J Antimicrob Chemother 62: ii105-ii114 [Abstract] [Full Text]  
  • Passarell, J. A., Meagher, A. K., Liolios, K., Cirincione, B. B., Van Wart, S. A., Babinchak, T., Ellis-Grosse, E. J., Ambrose, P. G. (2008). Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Intra-Abdominal Infections. Antimicrob. Agents Chemother. 52: 204-210 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»